NeoGenomics announces receipt of the first samples from the SURVIVE clinical trial, a large multi-site, prospectively randomized study in collaboration with the University of Ulm, Germany, that utilizes RaDaR for recurrence monitoring and potential intervention across sub-types of breast cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NEO:
- NeoGenomics price target raised to $16 from $15 at BofA
- NeoGenomics price target lowered to $22 from $23 at TD Cowen
- NEO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- NeoGenomics price target lowered to $16 from $18 at Morgan Stanley
- NeoGenomics announces commercial availability of two new tests
